Renalytix enters $15M at-the-market equity offering with H.C. Wainwright

Renalytix plc

Company may sell ADSs with aggregate offering price up to $15M on Nasdaq through H.C. Wainwright.
Placement fee of 3% of gross sales; company reimburses certain agent expenses.
Agreement effective May 15, 2024; no obligation to sell any ADSs.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Renalytix plc entered into Sales Agreement with H.C. Wainwright & Co., LLC valued at up to $15 million (effective 2024-05-15).

Action: entry
Agreement: atm program
Counterparty: H.C. Wainwright & Co., LLC
Value: up to $15 million
Effective: 2024-05-15

Exact text from the filing

On May 15, 2024, Renalytix plc (the “ Company ”) entered into an at the market offering agreement (the “ Sales Agreement ”) with H.C. Wainwright & Co., LLC (the “ Agent ”), pursuant to which the Company may issue and sell from time to time, at its option, the Company’s American Depositary Shares (the “ ADSs ”), each representing two ordinary shares (nominal value £0.0025 per share) of the Company, through or to the Agent, as sales agent and/or principal.

View on SEC.gov

284 material agreements filed in the last 30 days. Browse all material agreements →

Renalytix plc filing history →

Source: SEC EDGAR

accession 0000950170-24-060084

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.